---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-048643"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2022-02-22T23:59:59+00:00"
generated_at: "2026-06-27T06:10:47.149218+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Director David Schaffer resigns from 4D Molecular Therapeutics board

## Summary
- David Schaffer resigned from the Board and its Nominating and Corporate Governance and Science & Technology Committees, effective February 17, 2022.
- He also intends to terminate his consulting agreement with the Company.
- Resignation is not due to any disagreement with the Company or Board regarding operations, policies, or practices.

## SEC filing metadata
- accession: 0001193125-22-048643
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2022-02-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000119312522048643/0001193125-22-048643-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000119312522048643/d323690d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-048643
- JSON: https://secwatch.observer/filing/0001193125-22-048643.json
- Plain text: https://secwatch.observer/filing/0001193125-22-048643.txt

## Key facts
- Executive change
  David Schaffer resigned as Director at 4D Molecular Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On February 17, 2022, David Schaffer, Ph.D. delivered notice of his resignation from the Board of Directors (the "Board") of 4D Molecular Therapeutics, Inc. (the "Company") including his roles on the Nominating and Corporate Governance Committee and Science & Technology Committee, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650648/000119312522048643/0001193125-22-048643-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.